



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/062,811	01/31/2002	Thomas Victor Magee	PCI1895A	5184

23913 7590 04/15/2002

PFIZER INC
150 EAST 42ND STREET
5TH FLOOR - STOP 49
NEW YORK, NY 10017-5612

EXAMINER

AULAKH, CHARANJIT

ART UNIT PAPER NUMBER

1625

DATE MAILED: 04/15/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
10/062,811

Applicant(s)

Magee, T. V. et al.

Examiner
CHARANJIT AULAKH

Art Unit
1625

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on _____
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-22 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claims 1-22 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- *See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892) 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) ☐ Notice of Informal Patent Application (PTO-152)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) ☐ Other: _____

Art Unit: 1625

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents C and both B1 and B2 represent saturated or unsaturated carbocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 546, subclass 316.

II. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents N and both B1 and B2 represent saturated or unsaturated carbocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 544, subclass 333.

III. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents C and both B1 and B2 represent saturated or unsaturated heterocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 540, subclass 450.

IV. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents N and both B1 and B2 represent saturated or unsaturated heterocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 540, subclass 470.

Art Unit: 1625

V. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents C, B1 represents a saturated or unsaturated carbocyclic ring and B2 represents a saturated or unsaturated heterocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 546, subclass 255.

VI. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents N, B1 represents a saturated or unsaturated carbocyclic ring and B2 represents a saturated or unsaturated heterocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 544, subclass 242.

VII. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents C, B1 represents a saturated or unsaturated heterocyclic ring and B2 represents a saturated or unsaturated carbocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 546, subclass 268.1.

VIII. Claims 1-22, drawn to compounds of formula (1.0.0) where Y represents N, B1 represents a saturated or unsaturated heterocyclic ring and B2 represents a saturated or unsaturated carbocyclic ring, pharmaceutical compositions containing these compounds and a method of using these compounds, classified in class 544, subclass 298.

2. The inventions I through VIII as defined above are patentably distinct, each from the other since they are structurally so divergent that a reference showing compounds of invention I would not render compounds of inventions II through VIII prima facie obvious. Search required for e.g ; compounds of invention I in class 546, subclass 316 is not the same search required for e.g ;

Art Unit: 1625

compounds of invention II in class 544, subclass 333 and therefore, constitutes a burdensome search. Thus, restriction requirement as indicated above is proper.

3. A telephone call was made to the applicant's attorney, Mr. Raymond M. Speer on April 11, 2002 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chana Aulakh whose telephone number is (703) 305-4482. The examiner can normally be reached on "Monday-Thursday" from 7:30 A.M. to 6:00 P.M.

If the attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Alan Rotman, can be reached on (703) 308-4698. The fax number for this Group is (703) 308-4556.

Art Unit: 1625

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group's receptionist whose telephone number is (703) 308-1235.

A handwritten signature in black ink, reading "C. S. Aulakh". The signature is written in a cursive style with a large, sweeping "C" and "A".

CHARANJIT S. AULAKH

PRIMARY EXAMINER